{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:17:54Z","timestamp":1783707474894,"version":"3.55.0"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA189806"],"award-info":[{"award-number":["R01CA189806"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>During the COVID-19 pandemic, concerns emerged that hospital-based care could increase the risk of SARS-CoV-2 infection among pediatric patients with cancer, especially in resource-limited settings where the capacity to isolate patients would be challenging. Yet, infection rates in this population remain poorly documented, and it is unclear whether prior common human coronavirus (HCoV) exposures influence SARS-CoV-2 antibody responses. Here, we used serology to estimate SARS-CoV-2 exposure in children with and without cancer from Western Kenya and evaluated responses to common HCoVs to explore cross-reactivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed multiplex antibody profiling to assess SARS-CoV-2 and HCoV-specific responses in plasma from children with and without cancer sampled between 2014 and 2022. Unsupervised clustering identified participants with elevated SARS-CoV-2 seroreactivity relative to pre-pandemic samples. Seropositivity was further defined using a multi-antigen approach based on IgG levels to nucleocapsid and receptor-binding domain antigens to improve specificity. Cross-reactivity and cross-boosting by common HCoVs were evaluated through correlation analyses and groupwise comparisons of antibody levels, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 564 children, 474 were healthy (184 pre-pandemic; 290 post-pandemic) and 90 had cancer (16 pre-pandemic; 74 post-pandemic). Post-pandemic, 69% (200) of healthy controls exhibited elevated SARS-CoV-2 seroreactivity, with 51% (148) meeting the criteria for seropositivity. Children with cancer showed similar rates of seroreactivity (67%) and seropositivity (57%) after adjusting for sampling year, with incidence increasing annually from 2020 to 2022. Pre-pandemic samples exhibited weak cross-reactivity to HCoV-OC43 which increased following SARS-CoV-2 infection; however, no significant boosting of HCoV antibodies was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings indicate widespread SARS-CoV-2 exposure among children in Western Kenya and provide no evidence that hospitalization heightened infection risk for pediatric patients with cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0353284","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:47:46Z","timestamp":1783705666000},"page":"e0353284","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating SARS-CoV-2 exposure in asymptomatic hospitalized children with cancer in Western Kenya: A retrospective analysis of serological data"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2425-676X","authenticated-orcid":true,"given":"Katarina M.","family":"DiLillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine S.","family":"Forconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Matta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeni","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Tonui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Festus","family":"N\u2019juguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana A.","family":"Otieno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boaz","family":"Odwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Kinyua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Lauffenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Moormann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"5","key":"pone.0353284.ref001","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2352-4642(21)00031-6","article-title":"Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study","volume":"5","author":"D Graetz","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"pone.0353284.ref002","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s43018-024-00880-4","article-title":"The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis","volume":"6","author":"R Shah","year":"2025","journal-title":"Nat Cancer"},{"issue":"7","key":"pone.0353284.ref003","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S1470-2045(19)30273-6","article-title":"Global childhood cancer survival estimates and priority-setting: a simulation-based analysis","volume":"20","author":"ZJ Ward","year":"2019","journal-title":"Lancet Oncol"},{"key":"pone.0353284.ref004","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28571","article-title":"Patient management in pediatric oncology during the COVID-19 pandemic: report from francophone Africa","volume":"68","author":"F Traor\u00e9","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"pone.0353284.ref005","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/GO.20.00564","article-title":"Cancer and COVID-19 experiences at African cancer centers: the silver lining","volume":"7","author":"L Grossheim","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"pone.0353284.ref006","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/GO.20.00569","article-title":"Impact of COVID-19 on cancer care delivery in Africa: a cross-sectional survey of oncology providers in Africa","volume":"7","author":"YM Martei","year":"2021","journal-title":"JCO Glob Oncol"},{"issue":"2","key":"pone.0353284.ref007","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jamapediatrics.2020.4573","article-title":"Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis","volume":"175","author":"RM Viner","year":"2021","journal-title":"JAMA Pediatr"},{"key":"pone.0353284.ref008","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ijid.2021.07.060","article-title":"The toll of COVID-19 on African children: a descriptive analysis on COVID-19-related morbidity and mortality among the pediatric population in Sub-Saharan Africa","volume":"110","author":"S Rodriguez Vel\u00e1squez","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"9","key":"pone.0353284.ref009","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30517-X","article-title":"Serology testing in the COVID-19 pandemic response","volume":"20","author":"RW Peeling","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"pone.0353284.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004107","article-title":"Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: a systematic review and meta-analysis of standardized population-based studies","volume":"19","author":"I Bergeri","year":"2022","journal-title":"PLoS Med"},{"issue":"1","key":"pone.0353284.ref011","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1186\/s12879-022-07820-6","article-title":"Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021","volume":"22","author":"E Lyimo","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0353284.ref012","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s12879-025-10762-4","article-title":"Seroprevalence of anti-SARS-CoV-2 IgG antibodies among children attending the pediatric hospital in Bamako, Mali (BamaCoV-Kids Study)","volume":"25","author":"AI Maiga","year":"2025","journal-title":"BMC Infect Dis"},{"key":"pone.0353284.ref013","doi-asserted-by":"crossref","first-page":"101786","DOI":"10.1016\/j.eclinm.2022.101786","article-title":"SARS-CoV-2 seroprevalence in children worldwide: a systematic review and meta-analysis","volume":"56","author":"R Naeimi","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"12","key":"pone.0353284.ref014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0312554","article-title":"Seroprevalence of SARS-CoV-2 and risk factors for infection among children in Uganda: a serial cross-sectional study","volume":"19","author":"I Bagala","year":"2024","journal-title":"PLoS One"},{"issue":"6522","key":"pone.0353284.ref015","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.abe1107","article-title":"Preexisting and de novo humoral immunity to SARS-CoV-2 in humans","volume":"370","author":"KW Ng","year":"2020","journal-title":"Science"},{"issue":"7","key":"pone.0353284.ref016","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.02.010","article-title":"Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection","volume":"184","author":"EM Anderson","year":"2021","journal-title":"Cell"},{"key":"pone.0353284.ref017","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijid.2023.06.009","article-title":"Prepandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: systematic review and meta-analysis","volume":"134","author":"JPA Ioannidis","year":"2023","journal-title":"Int J Infect Dis"},{"key":"pone.0353284.ref018","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ijid.2020.10.104","article-title":"High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa","volume":"102","author":"FY Tso","year":"2021","journal-title":"Int J Infect Dis"},{"key":"pone.0353284.ref019","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2022-008793","article-title":"SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021","volume":"7","author":"HC Lewis","year":"2022","journal-title":"BMJ Glob Health"},{"issue":"5","key":"pone.0353284.ref020","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(21)00060-7","article-title":"Challenges in interpreting SARS-CoV-2 serological results in African countries","volume":"9","author":"A Nkuba Ndaye","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"6","key":"pone.0353284.ref021","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/ijc.30170","article-title":"Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: a historical cohort study","volume":"139","author":"G Buckle","year":"2016","journal-title":"Int J Cancer"},{"issue":"3","key":"pone.0353284.ref022","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/infdis\/jiac431","article-title":"SARS-CoV-2 serosurveys: how antigen, isotype and threshold choices affect the outcome","volume":"227","author":"RA Binder","year":"2023","journal-title":"J Infect Dis"},{"issue":"7","key":"pone.0353284.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0307568","article-title":"Minding the margins: evaluating the impact of COVID-19 among Latinx and Black communities with optimal qualitative serological assessment tools","volume":"19","author":"RA Binder","year":"2024","journal-title":"PLoS One"},{"issue":"4","key":"pone.0353284.ref024","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00193-22","article-title":"The serological sciences network (SeroNet) for COVID-19: depth and breadth of serology assays and plans for assay harmonization","volume":"7","author":"AB Karger","year":"2022","journal-title":"mSphere"},{"issue":"6","key":"pone.0353284.ref025","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac171","article-title":"Mission, organization, and future direction of the serological sciences network for COVID-19 (SeroNet) epidemiologic cohort studies","volume":"9","author":"JC Figueiredo","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"pone.0353284.ref026","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jim.2017.01.010","article-title":"Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles","volume":"443","author":"EP Brown","year":"2017","journal-title":"J Immunol Methods"},{"issue":"1","key":"pone.0353284.ref027","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1038\/s41467-023-39189-8","article-title":"Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination","volume":"14","author":"X Tong","year":"2023","journal-title":"Nat Commun"},{"key":"pone.0353284.ref028","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jmii.2020.04.011","article-title":"Coronavirus disease 2019 (COVID-19) in Kenya: preparedness, response and transmissibility","volume":"53","author":"MA Aluga","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"issue":"5","key":"pone.0353284.ref029","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41577-022-00809-x","article-title":"The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses","volume":"23","author":"SM Murray","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"pone.0353284.ref030","doi-asserted-by":"crossref","first-page":"103700","DOI":"10.1016\/j.ebiom.2021.103700","article-title":"Relative ratios of human seasonal coronavirus antibodies predict the efficiency of cross-neutralization of SARS-CoV-2 spike binding to ACE2","volume":"74","author":"Y Galipeau","year":"2021","journal-title":"EBioMedicine"},{"issue":"1","key":"pone.0353284.ref031","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/s41467-021-20973-3","article-title":"Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity","volume":"12","author":"M Becker","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0353284.ref032","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1038\/s41598-021-86035-2","article-title":"Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays","volume":"11","author":"C Fotis","year":"2021","journal-title":"Sci Rep"},{"key":"pone.0353284.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288557","article-title":"Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: a prospective longitudinal study","volume":"18","author":"H Amellal","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"pone.0353284.ref034","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1038\/s41467-021-24979-9","article-title":"Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses","volume":"12","author":"N Ortega","year":"2021","journal-title":"Nat Commun"},{"key":"pone.0353284.ref035","doi-asserted-by":"crossref","first-page":"836449","DOI":"10.3389\/fimmu.2022.836449","article-title":"Age-associated seroprevalence of coronavirus antibodies: population-based serosurveys in 2013 and 2020, British Columbia, Canada","volume":"13","author":"G Tanunliong","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"pone.0353284.ref036","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31212","article-title":"Seroprevalence of SARS-CoV-2 in pediatric hematology-oncology patients","volume":"71","author":"V Phan","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"pone.0353284.ref037","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000003140","article-title":"Estimated SARS-CoV-2 seroprevalence in healthy children and those with chronic illnesses in the washington metropolitan area as of october 2020","volume":"40","author":"B Bahar","year":"2021","journal-title":"Pediatr Infect Dis J"},{"issue":"15","key":"pone.0353284.ref038","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.3390\/jcm11154428","article-title":"Lower SARS-CoV-2 seroprevalence among cancer patients in sub-Saharan Africa","volume":"11","author":"FY Tso","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"pone.0353284.ref039","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1186\/s12889-022-14509-7","article-title":"Patterns and predictors of adherence to health-protective measures during COVID-19 pandemic in the UK: cross-sectional and longitudinal findings from the HEBECO study","volume":"22","author":"D Kale","year":"2022","journal-title":"BMC Public Health"},{"issue":"8","key":"pone.0353284.ref040","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2021.2159","article-title":"Difference in SARS-CoV-2 antibody status between patients with cancer and health care workers during the COVID-19 pandemic in Japan","volume":"7","author":"S Yazaki","year":"2021","journal-title":"JAMA Oncol"},{"key":"pone.0353284.ref041","doi-asserted-by":"crossref","first-page":"919762","DOI":"10.3389\/fimmu.2022.919762","article-title":"Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection","volume":"13","author":"M Abu Shanap","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"pone.0353284.ref042","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"A Thakkar","year":"2021","journal-title":"Cancer Cell"},{"key":"pone.0353284.ref043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000883","article-title":"SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021","volume":"2","author":"AO Etyang","year":"2022","journal-title":"PLOS Global Public Health"},{"issue":"9","key":"pone.0353284.ref044","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13173","article-title":"SARS-CoV-2 seroprevalence and implications for population immunity: evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022","volume":"17","author":"EW Kagucia","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"issue":"6570","key":"pone.0353284.ref045","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1126\/science.abk0414","article-title":"COVID-19 transmission dynamics underlying epidemic waves in Kenya","volume":"374","author":"SPC Brand","year":"2021","journal-title":"Science"},{"issue":"1","key":"pone.0353284.ref046","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12985-023-02018-x","article-title":"A comparison of transmissibility of SARS-CoV-2 variants of concern","volume":"20","author":"SS Manathunga","year":"2023","journal-title":"Virol J"},{"key":"pone.0353284.ref047","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s43856-022-00167-8","article-title":"Temporal lineage replacements and dominance of imported variants of concern during the COVID-19 pandemic in Kenya","volume":"2","author":"G Kimita","year":"2022","journal-title":"Commun Med (Lond)"},{"issue":"3","key":"pone.0353284.ref048","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofag084","article-title":"Longitudinal epidemiology and variant dynamics of SARS-CoV-2 in Coastal Kenya (2020-2025): clinical features and wave patterns","volume":"13","author":"AW Lambisia","year":"2026","journal-title":"Open Forum Infect Dis"},{"key":"pone.0353284.ref049","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijid.2023.11.008","article-title":"Pre-existing cross-reactive neutralizing activity against SARS-CoV-2 and seasonal coronaviruses prior to the COVID-19 pandemic (2014-2019) with limited immunity against recent emerging SARS-CoV-2 variants, Vietnam","volume":"139","author":"TTN Nguyen","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"5","key":"pone.0353284.ref050","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1803","article-title":"Absence of severe acute respiratory syndrome coronavirus 2 neutralizing activity in prepandemic sera from individuals with recent seasonal coronavirus infection","volume":"73","author":"D Poston","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0353284.ref051","doi-asserted-by":"crossref","first-page":"22175","DOI":"10.1038\/s41598-022-26709-7","article-title":"Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 spike protein","volume":"12","author":"S Lapidus","year":"2022","journal-title":"Sci Rep"},{"issue":"8","key":"pone.0353284.ref052","doi-asserted-by":"crossref","first-page":"104766","DOI":"10.1016\/j.isci.2022.104766","article-title":"Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants","volume":"25","author":"M Emmenegger","year":"2022","journal-title":"iScience"},{"issue":"9","key":"pone.0353284.ref053","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3390\/v14091861","article-title":"SARS-CoV-2 RBD-specific antibodies induced early in the pandemic by natural infection and vaccination display cross-variant binding and inhibition","volume":"14","author":"MR Walker","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"pone.0353284.ref054","doi-asserted-by":"crossref","first-page":"7733","DOI":"10.1038\/s41467-022-35456-2","article-title":"Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones","volume":"13","author":"NS Lima","year":"2022","journal-title":"Nat Commun"},{"key":"pone.0353284.ref055","article-title":"Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals","volume":"2","author":"A Tarke","year":"2021","journal-title":"Cell Rep Med"},{"issue":"18","key":"pone.0353284.ref056","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.142386","article-title":"Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity","volume":"5","author":"KM McAndrews","year":"2020","journal-title":"JCI Insight"},{"issue":"7918","key":"pone.0353284.ref057","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-022-04865-0","article-title":"Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination","volume":"607","author":"RK Suryawanshi","year":"2022","journal-title":"Nature"},{"issue":"6","key":"pone.0353284.ref058","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2022.03.029","article-title":"SARS-CoV-2 omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals","volume":"30","author":"SI Richardson","year":"2022","journal-title":"Cell Host Microbe"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:47:59Z","timestamp":1783705679000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353284"}},"subtitle":[],"editor":[{"given":"Glenda","family":"Canderan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":58,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0353284","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}